VIA EDGAR

 

June 25, 2021

 

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

Attn:	Kasey Robinson
	Christopher Edwards

 

Re:	Aerovate Therapeutics, Inc.
	Acceleration Request for Registration Statement on Form S-1
	File No. 333-256949

 

	Requested Date:	June 29, 2021
	Requested Time:	4:30 p.m. Eastern Standard Time

 

Dear Ms. Robinson and Mr. Edwards:

 

In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), Jefferies LLC, Cowen and Company, LLC and Evercore Group L.L.C., as representatives of the several underwriters, hereby join Aerovate Therapeutics, Inc. in requesting that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to June 29, 2021, at 4:30 p.m., Eastern Time, or as soon thereafter as practicable.

 

Pursuant to Rule 460 under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus, to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.

 

We have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, to the extent applicable.

 

[Signature Page Follows]

 

 

Very truly yours,

 

As representatives of the several underwriters

 

JEFFERIES LLC

 

By:	/s/ Matthew Kim
	Name:Matthew Kim
	Title:Managing Director, Joint Head of US Biotechnology

 

COWEN AND COMPANY, LLC

 

By:	/s/ Bill Follis
	Name:Bill Follis
	Title:Managing Director

 

EVERCORE GROUP L.L.C.

 

By:	/s/ Maren Winnick
	Name:Maren Winnick
	Title:Senior Managing Director, Advisory